FY2028 EPS Estimates for Personalis Cut by HC Wainwright

Personalis, Inc. (NASDAQ:PSNL) – Equities researchers at HC Wainwright dropped their FY2028 earnings per share (EPS) estimates for shares of Personalis in a research report issued to clients and investors on Thursday, November 7th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.40 for the year, down from their prior forecast of $0.53. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Personalis’ current full-year earnings is ($1.15) per share.

A number of other brokerages have also commented on PSNL. Needham & Company LLC reissued a “buy” rating and set a $7.25 price objective on shares of Personalis in a report on Thursday. BTIG Research increased their price objective on Personalis from $5.50 to $7.00 and gave the company a “buy” rating in a report on Friday, August 16th.

Personalis Stock Performance

Shares of NASDAQ PSNL opened at $4.32 on Friday. The firm has a market cap of $229.31 million, a price-to-earnings ratio of -2.63 and a beta of 1.94. The business’s 50-day simple moving average is $5.15 and its 200-day simple moving average is $3.32. Personalis has a 52 week low of $0.89 and a 52 week high of $7.20.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.10. The business had revenue of $22.58 million for the quarter, compared to analyst estimates of $19.81 million. Personalis had a negative return on equity of 56.87% and a negative net margin of 101.78%. During the same quarter in the prior year, the firm posted ($0.50) EPS.

Institutional Trading of Personalis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP grew its holdings in shares of Personalis by 6.2% during the 1st quarter. GSA Capital Partners LLP now owns 420,141 shares of the company’s stock worth $626,000 after purchasing an additional 24,498 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Personalis by 90.7% during the 1st quarter. Acadian Asset Management LLC now owns 991,828 shares of the company’s stock worth $1,476,000 after purchasing an additional 471,646 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in shares of Personalis by 144.7% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 821,657 shares of the company’s stock worth $1,224,000 after purchasing an additional 485,822 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Personalis during the 1st quarter worth approximately $29,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Personalis by 58.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 95,000 shares of the company’s stock worth $142,000 after purchasing an additional 34,900 shares in the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.